Benzinga · Aug 10, 2026
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
NASDAQ · CTMX
CytomX Therapeutics, Inc.
Healthcare · Biotechnology
$3.36
Up+$0.01 (+0.30%)
Updated Aug 16, 2026, 7:55 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 686.8M
- P/E ratio
- 23.88
- Dividend yield
- 0.00%
- 52-week range
- $2.82 – $8.21
- Volume
- 1.43M
- Avg. volume
- 3.54M
Price performance
CTMX price history
1M range · 20 trading sessions · Daily adjusted prices
CTMX closed at $3.36 after 20 trading sessions, down 4.55% for the selected period.
- Last close
- $3.36
- Period change
- -4.55%
- Period low
- $3.10
- Period high
- $3.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $3.34 | $3.385 | $3.28 | $3.36 | 1.43M |
| Aug 13, 2026 | $3.50 | $3.50 | $3.34 | $3.35 | 1.81M |
| Aug 12, 2026 | $3.48 | $3.535 | $3.415 | $3.49 | 2.52M |
| Aug 11, 2026 | $3.42 | $3.50 | $3.37 | $3.45 | 1.7M |
| Aug 10, 2026 | $3.45 | $3.495 | $3.385 | $3.44 | 1.8M |
| Aug 7, 2026 | $3.32 | $3.55 | $3.30 | $3.46 | 2.46M |
| Aug 6, 2026 | $3.31 | $3.40 | $3.29 | $3.37 | 1.94M |
| Aug 5, 2026 | $3.30 | $3.375 | $3.27 | $3.35 | 2.03M |
| Aug 4, 2026 | $3.23 | $3.33 | $3.215 | $3.32 | 2.44M |
| Aug 3, 2026 | $3.09 | $3.18 | $3.01 | $3.17 | 3.8M |
| Jul 31, 2026 | $3.26 | $3.281 | $3.10 | $3.10 | 3.5M |
| Jul 30, 2026 | $3.18 | $3.29 | $3.155 | $3.28 | 1.76M |
| Jul 29, 2026 | $3.21 | $3.35 | $3.15 | $3.17 | 1.37M |
| Jul 28, 2026 | $3.26 | $3.274 | $3.13 | $3.22 | 2.01M |
| Jul 27, 2026 | $3.25 | $3.43 | $3.25 | $3.25 | 2.5M |
| Jul 24, 2026 | $3.34 | $3.38 | $3.20 | $3.24 | 1.52M |
| Jul 23, 2026 | $3.31 | $3.405 | $3.275 | $3.33 | 1.38M |
| Jul 22, 2026 | $3.40 | $3.44 | $3.325 | $3.33 | 2.31M |
| Jul 21, 2026 | $3.50 | $3.545 | $3.39 | $3.42 | 5.96M |
| Jul 20, 2026 | $3.65 | $3.735 | $3.505 | $3.52 | 5.54M |
Latest CTMX news
The latest Smart Investors Daily articles mentioning CTMX.
Stock researchCompany · Overview
CTMX research
Overview
Company profile and research snapshot.
Company profile
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.50
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | JP Morgan | Overweight | — |
| Aug 10, 2026 | Guggenheim | Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 23, 2026 | Piper Sandler | Overweight | — |
| Mar 19, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 7, 2026
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
Strong clinical progress and expanded Regeneron collaboration bolster CytomX's path forward despite revenue decline and safety considerations.
Yahoo · Aug 7, 2026
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv
ChartMill · Aug 7, 2026
CytomX Therapeutics (NASDAQ:CTMX) Shares Plunge After Q2 Revenue and EPS Miss Estimates
Cytomx (CTMX) shares fell ~30% after Q2 revenue and EPS missed estimates. Lead program Varseta-M Phase 1 data expected by end of 2026.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
